Bendamustine - Astellas Pharma GmbH

Drug Profile

Bendamustine - Astellas Pharma GmbH

Alternative Names: BENDA; Bendam; Bendamus; Bendamustine HCl; Bendamustine hydrochloride; Bentaman; Cytostasan; Endexin; Esevaril; Innomustine; Levact; Ribomustin; Ribomustine; Ribovact; SDX-105; SyB L-0501; Symbenda; Treakisym; Treanda

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jenapharm
  • Developer Astellas Pharma GmbH; Cantonal Hospital of St Gallen; Eisai Co Ltd; Foundation GIMEMA; GlaxoSmithKline KK; INNOPHARMAX; Istituto Clinico Humanitas; Janssen-Cilag; Memorial Sloan-Kettering Cancer Center; Mundipharma International; Northside Hospital; PETHEMA Foundation; St. Jude Childrens Research Hospital; SymBio Pharmaceuticals; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents; Antimetabolites; Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Mitosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Cancer; Chronic lymphocytic leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Marginal-zone-B-cell-lymphoma
  • Phase I Solid tumours
  • No development reported Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 21 Jan 2018 Phase-I clinical trials in Solid tumours in Japan (PO)
  • 15 Jan 2018 SymBio initiates enrolment in a phase III trial for Diffuse large B cell lymphoma (Second-line therapy or greater) in Japan (IV)
  • 10 Jan 2018 Cephalon terminates a phase II trial as the PI left the institution before all data analysis was completed in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT01315873)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top